Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
Oxaliplatin-based chemotherapy is used to treat patients with esophageal adenocarcinoma (EAC), but no biomarkers are currently available for patient selection. We performed a prospective, clinical trial to identify potential biomarkers associated with clinical outcomes. Tumor tissue was obtained fro...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Publishing Group
2018
|
| _version_ | 1826272536338366464 |
|---|---|
| author | MacGregor, T Carter, R Gillies, R Findlay, J Kartsonaki, C Castro-Giner, F Sahgal, N Wang, L Chetty, R Maynard, N Cazier, J Buffa, F McHugh, P Tomlinson, I Middleton, M Sharma, R |
| author_facet | MacGregor, T Carter, R Gillies, R Findlay, J Kartsonaki, C Castro-Giner, F Sahgal, N Wang, L Chetty, R Maynard, N Cazier, J Buffa, F McHugh, P Tomlinson, I Middleton, M Sharma, R |
| author_sort | MacGregor, T |
| collection | OXFORD |
| description | Oxaliplatin-based chemotherapy is used to treat patients with esophageal adenocarcinoma (EAC), but no biomarkers are currently available for patient selection. We performed a prospective, clinical trial to identify potential biomarkers associated with clinical outcomes. Tumor tissue was obtained from 38 patients with resectable EAC before and after 2 cycles of oxaliplatin-fluorouracil chemotherapy. Pre-treatment mRNA expression of 280 DNA repair (DNAR) genes was tested for association with histopathological regression at surgery, disease-free survival (DFS) and overall survival (OS). High expression of 13 DNA damage repair genes was associated with DFS less than one year (P < 0.05); expression of 11 DNAR genes were associated with worse OS (P < 0.05). From clinical associations with outcomes, two genes, ERCC1 and EME1, were identified as candidate biomarkers. In cell lines in vitro, we showed the mechanism of action related to repair of oxaliplatin-induced DNA damage by depletion and knockout of protein binding partners of the candidate biomarkers, XPF and MUS81 respectively. In clinical samples from the clinical trial, pre-treatment XPF protein levels were associated with pathological response, and MUS81 protein was associated with 1-year DFS. XPF and MUS81 merit further validation in prospective clinical trials as biomarkers that may predict clinical response of EAC to oxaliplatin-based chemotherapy. |
| first_indexed | 2024-03-06T22:14:06Z |
| format | Journal article |
| id | oxford-uuid:52d1b797-0d1e-4e4a-a69f-a3640907a253 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:14:06Z |
| publishDate | 2018 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:52d1b797-0d1e-4e4a-a69f-a3640907a2532022-03-26T16:27:44ZTranslational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinomaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:52d1b797-0d1e-4e4a-a69f-a3640907a253EnglishSymplectic Elements at OxfordNature Publishing Group2018MacGregor, TCarter, RGillies, RFindlay, JKartsonaki, CCastro-Giner, FSahgal, NWang, LChetty, RMaynard, NCazier, JBuffa, FMcHugh, PTomlinson, IMiddleton, MSharma, ROxaliplatin-based chemotherapy is used to treat patients with esophageal adenocarcinoma (EAC), but no biomarkers are currently available for patient selection. We performed a prospective, clinical trial to identify potential biomarkers associated with clinical outcomes. Tumor tissue was obtained from 38 patients with resectable EAC before and after 2 cycles of oxaliplatin-fluorouracil chemotherapy. Pre-treatment mRNA expression of 280 DNA repair (DNAR) genes was tested for association with histopathological regression at surgery, disease-free survival (DFS) and overall survival (OS). High expression of 13 DNA damage repair genes was associated with DFS less than one year (P < 0.05); expression of 11 DNAR genes were associated with worse OS (P < 0.05). From clinical associations with outcomes, two genes, ERCC1 and EME1, were identified as candidate biomarkers. In cell lines in vitro, we showed the mechanism of action related to repair of oxaliplatin-induced DNA damage by depletion and knockout of protein binding partners of the candidate biomarkers, XPF and MUS81 respectively. In clinical samples from the clinical trial, pre-treatment XPF protein levels were associated with pathological response, and MUS81 protein was associated with 1-year DFS. XPF and MUS81 merit further validation in prospective clinical trials as biomarkers that may predict clinical response of EAC to oxaliplatin-based chemotherapy. |
| spellingShingle | MacGregor, T Carter, R Gillies, R Findlay, J Kartsonaki, C Castro-Giner, F Sahgal, N Wang, L Chetty, R Maynard, N Cazier, J Buffa, F McHugh, P Tomlinson, I Middleton, M Sharma, R Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma |
| title | Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma |
| title_full | Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma |
| title_fullStr | Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma |
| title_full_unstemmed | Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma |
| title_short | Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma |
| title_sort | translational study identifies xpf and mus81 as predictive biomarkers for oxaliplatin based peri operative chemotherapy in patients with esophageal adenocarcinoma |
| work_keys_str_mv | AT macgregort translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT carterr translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT gilliesr translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT findlayj translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT kartsonakic translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT castroginerf translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT sahgaln translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT wangl translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT chettyr translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT maynardn translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT cazierj translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT buffaf translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT mchughp translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT tomlinsoni translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT middletonm translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma AT sharmar translationalstudyidentifiesxpfandmus81aspredictivebiomarkersforoxaliplatinbasedperioperativechemotherapyinpatientswithesophagealadenocarcinoma |